On Nov. 8–9, researchers, physicians, movement disorder specialists and healthcare professionals convened in Toronto for the 3rd Annual Canadian Movement Disorders Meeting. Their goal, to share the latest research and experiences in the field of movement disorders and learn from others in the field. This included the latest advancements in Parkinson’s research and treatment.  

Although much of the conference was highly technical, here are some high-level takeaways that were discussed: 

• Ongoing work on defining a biology-based classification of PD to design and optimize early interventions and targeted disease-modifying treatments. 

• Research on the markers of neurodegeneration and new ways to detect it with imaging. 

• Discussions about C-OPN, the geographic distribution of research participants, and improving access to clinical trials nationwide. 

• New developments in machine learning show potential to help with diagnosis and disease management. 

In addition to the takeaways above, there were two interesting conversations from the conference that we’d like to highlight. 

The first was a debate around the use of wearable devices in detecting and managing Parkinson’s. These tools, which take the form of smartwatches, sensors, and other body-worn technologies, are already being used in research settings to track symptoms like tremors, gait, balance, and overall movement. The right application of this technology could allow people with Parkinson’s to more precisely track their clinical progression. Researchers discussed topics such as the potential of these devices, their accessibility, and whether their use in Parkinson’s treatment is ready for widespread adoption.  

The second was about the Canadian experience with continuous subcutaneous levodopa, and whether it has become a game changer for Canadians living with Parkinson’s. You may recall that this treatment became available to Canadians earlier this year. Researchers discussed both sides of this topic, with some highlighting that it is safe and effective, and preferred by many patients due to its ease of use. Other researchers argued that it is expensive, and some patients using it have adverse side effects. 

Although neither of these topics had a universal consensus, they both highlight the importance of conferences such as the Movement Disorders Meeting. They serve not only as a place to learn, but also as a forum where leaders in their fields can debate topics which have a direct impact on patient’s lives. As research progresses and these technologies become more refined, we can look forward to a future where Parkinson’s care is more tailored, efficient, and accessible than ever before. The key takeaway from the meeting is clear: collaboration between researchers, clinicians, and patients is essential to unlocking these breakthroughs and ensuring that they benefit as many people as possible.